Download
s12883-021-02532-x.pdf 1,39MB
WeightNameValue
1000 Titel
  • Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
1000 Autor/in
  1. Barz, Melanie |
  2. Bette, Stefanie |
  3. Janssen, Insa |
  4. Aftahy, A. Kaywan |
  5. Huber, Thomas |
  6. Liesche-Starnecker, Friederike |
  7. Ryang, Yu-Mi |
  8. Wiestler, Benedikt |
  9. Combs, Stephanie E. |
  10. Meyer, Bernhard |
  11. Gempt, Jens |
1000 Verlag
  • BioMed Central
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-01-21
1000 Erschienen in
1000 Quellenangabe
  • 22(1):32
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12883-021-02532-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780246/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>For recurrent glioblastoma (GB) patients, several therapy options have been established over the last years such as more aggressive surgery, re-irradiation or chemotherapy. Age and the Karnofsky Performance Status Scale (KPSS) are used to make decisions for these patients as these are established as prognostic factors in the initial diagnosis of GB. This study’s aim was to evaluate preoperative patient comorbidities by using the age-adjusted Charlson Comorbidity Index (ACCI) as a prognostic factor for recurrent GB patients.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>In this retrospective analysis we could include 123 patients with surgery for primary recurrence of GB from January 2007 until December 2016 (43 females, 80 males, mean age 57 years (range 21–80 years)). Preoperative age, sex, ACCI, KPSS and adjuvant treatment regimes were recorded for each patient. Extent of resection (EOR) was recorded as a complete/incomplete resection of the contrast-enhancing tumor part.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Median overall survival (OS) was 9.0 months (95% CI 7.1–10.9 months) after first re-resection. Preoperative KPSS &gt; 80% (<jats:italic>P</jats:italic> &lt; 0.001) and EOR (<jats:italic>P</jats:italic> = 0.013) were associated with significantly improved survival in univariate analysis. Including these factors in multivariate analysis, preoperative KPSS &lt; 80 (HR 2.002 [95% CI: 1.246–3.216], <jats:italic>P</jats:italic> = 0.004) and EOR are the only significant prognostic factor (HR 1.611 [95% CI: 1.036–2.505], <jats:italic>P</jats:italic> = 0.034). ACCI was not shown as a prognostic factor in univariate and multivariate analyses.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>For patients with surgery for recurrent glioblastoma, the ACCI does not add further information about patient’s prognosis besides the well-established KPSS and extent of resection.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Age-adjusted Charlson comorbidity index
lokal Female [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Glioblastoma/surgery [MeSH]
lokal Humans [MeSH]
lokal Retrospective Studies [MeSH]
lokal Glioblastoma/epidemiology [MeSH]
lokal Middle Aged [MeSH]
lokal Brain Neoplasms/epidemiology [MeSH]
lokal Prognostic factor
lokal Medical and Health Sciences
lokal Male [MeSH]
lokal Recurrent glioblastoma
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Comorbidity [MeSH]
lokal Surgery
lokal Research Article
lokal Karnofsky Performance Status [MeSH]
lokal Brain Neoplasms/therapy [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-8734-9309|https://frl.publisso.de/adhoc/uri/QmV0dGUsIFN0ZWZhbmll|https://frl.publisso.de/adhoc/uri/SmFuc3NlbiwgSW5zYQ==|https://frl.publisso.de/adhoc/uri/QWZ0YWh5LCBBLiBLYXl3YW4=|https://frl.publisso.de/adhoc/uri/SHViZXIsIFRob21hcw==|https://frl.publisso.de/adhoc/uri/TGllc2NoZS1TdGFybmVja2VyLCBGcmllZGVyaWtl|https://frl.publisso.de/adhoc/uri/UnlhbmcsIFl1LU1p|https://frl.publisso.de/adhoc/uri/V2llc3RsZXIsIEJlbmVkaWt0|https://frl.publisso.de/adhoc/uri/Q29tYnMsIFN0ZXBoYW5pZSBFLg==|https://frl.publisso.de/adhoc/uri/TWV5ZXIsIEJlcm5oYXJk|https://frl.publisso.de/adhoc/uri/R2VtcHQsIEplbnM=
1000 Hinweis
  • DeepGreen-ID: aa983cd2895e4d39841679b03e6510f5 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Technische Universität München |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Technische Universität München |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6485137.rdf
1000 Erstellt am 2024-10-02T17:53:06.055+0200
1000 Erstellt von 322
1000 beschreibt frl:6485137
1000 Zuletzt bearbeitet 2025-08-06T15:19:16.742+0200
1000 Objekt bearb. Wed Aug 06 15:19:16 CEST 2025
1000 Vgl. frl:6485137
1000 Oai Id
  1. oai:frl.publisso.de:frl:6485137 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source